Findings

What do systematic reviews say?

1 questions · 1 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 100%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Overall response rate · people with advanced biliary tract carcinomas

It is very uncertain whether gemcitabine plus vandetanib changes overall response rate compared with vandetanib (very low certainty).

1 finding from 1 review

Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
RR 5.4 [1.25, 23.29]
1 study · 113 participants
Very low